Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
- 2 January 2015
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Metabolism Reviews
- Vol. 47 (1), 21-28
- https://doi.org/10.3109/03602532.2014.1003648
Abstract
Mechanism-based inactivation (MBI) of CYP450 enzymes is a unique form of inhibition in which the enzymatic machinery of the victim is responsible for generation of the reactive metabolite. This precondition sets up a time-dependency for the inactivation process, a hallmark feature that characterizes all MBI. Yet, MBI itself is a complex biochemical phenomenon that operates in different modes, namely, covalent binding to apoprotein, covalent binding of the porphyrin group and also complexation of the catalytic iron. Using lapatinib as a recent example of toxicological interest, we present an example of a mixed-function MBI that can confound clinical drug–drug interactions manifestation. Lapatinib exhibits both covalent binding to the apoprotein and formation of a metabolite-intermediate complex in an enzyme-selective manner (CYP3A4 versus CYP3A5), each with different reactive metabolites. The clinical implication of this effect is also contingent upon genetic polymorphisms of the enzyme involved as well as the co-administration of other substrates, inhibitors or inducers, culminating in drug–drug interactions. This understanding recapitulates the importance of applying isoform-specific mechanistic investigations to develop customized strategies to manage such outcomes.Keywords
This publication has 37 references indexed in Scilit:
- Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidenceBreast Cancer Research and Treatment, 2012
- Identification of the Residue in Human CYP3A4 That Is Covalently Modified by Bergamottin and the Reactive Intermediate That Contributes to the Grapefruit Juice EffectDrug Metabolism and Disposition, 2012
- Potent mechanism‐based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substratesBritish Journal of Pharmacology, 2011
- Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by LapatinibDrug Metabolism and Disposition, 2011
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast CancerJournal of Clinical Oncology, 2011
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by LapatinibMolecular Pharmacology, 2010
- LapatinibDrugs, 2009
- Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjectsBritish Journal of Clinical Pharmacology, 2009
- Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyriasBritish Journal of Clinical Pharmacology, 2007
- A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecanAnnals of Oncology, 2007